Neurocrine Biosciences Unveils Two-Year CRENESSITY Data at ENDO 2026: Promising Cardiometabolic Improvements

Promising Data on CRENESSITY® for Congenital Adrenal Hyperplasia

Overview
At the annual ENDO 2026 conference, Neurocrine Biosciences unveiled significant findings from the two-year Phase 3 CAHtalyst Adult study, revealing how CRENESSITY® (crinecerfont) improves health outcomes for adults impacted by classic congenital adrenal hyperplasia (CAH). The results shed light on cardiometabolic benefits and weight management associated with this innovative treatment.

Significant Findings
The two-year data reflected a notable reduction in insulin resistance, enhancements in body composition, and effective weight loss among participants. Specifically, among participants who began the study overweight or obese, approximately 37% achieved at least a 5% reduction in body weight over two years. Furthermore, 43% of those who initially showed signs of insulin resistance no longer did so two years later. The overarching trend highlighted a continual decrease in glucocorticoid (GC) doses while maintaining hormone balance, an essential consideration for patients with CAH.

Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences, articulated that, "These two-year results provide vital insights into the long-term impact of CRENESSITY. Sustained improvements highlight the potential of CRENESSITY to redefine lifelong management for adults with classic CAH," emphasizing its role in enhancing not only metabolic health but also overall quality of life.

Long-Term Benefits for Bone Health
In addition to cardiometabolic outcomes, the data showcased encouraging trends regarding bone health. Participants undergoing treatment exhibited improvements in bone mineral density, particularly remarkable in the lumbar spine region. This improvement is especially noteworthy given that glucocorticoid treatments can adversely affect bone health over time.

Patient Satisfaction and Quality of Life
Feedback from patient-reported surveys indicated substantial progress in the quality of life for participants. An impressive 96% expressed satisfaction with the CRENESSITY treatment, noting improvements in emotional well-being, energy levels, and overall confidence in managing their condition. With 98% reporting increased optimism regarding their future with classic CAH, these findings underscore the significance of patient-centric outcomes beyond mere clinical metrics.

Conclusions and Future Directions
This recent data release at ENDO 2026 reaffirms the therapeutic promise of CRENESSITY for adults with classic CAH, emphasizing its potential to reduce the long-term impacts associated with high-dose glucocorticoid therapies. Continued ongoing studies will further enrich our understanding of CRENESSITY’s benefits, not just in terms of physiological health, but in improving the emotional and psychological quality of life for individuals managing CAH. As the field becomes increasingly focused on holistic patient health, these findings mark an important step forward in the treatment landscape for congenital adrenal hyperplasia.